SE454402B - Nasalt administrerbar farmaceutisk komposition innehallande en ergotpeptidalkaloid samt ett xantin - Google Patents

Nasalt administrerbar farmaceutisk komposition innehallande en ergotpeptidalkaloid samt ett xantin

Info

Publication number
SE454402B
SE454402B SE8300495A SE8300495A SE454402B SE 454402 B SE454402 B SE 454402B SE 8300495 A SE8300495 A SE 8300495A SE 8300495 A SE8300495 A SE 8300495A SE 454402 B SE454402 B SE 454402B
Authority
SE
Sweden
Prior art keywords
composition according
composition
xanthine
hydrogen
nasal
Prior art date
Application number
SE8300495A
Other languages
English (en)
Swedish (sv)
Other versions
SE8300495L (sv
SE8300495D0 (sv
Inventor
J-R Kiechel
F Acezat-Mispelter
D Plas
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8300495D0 publication Critical patent/SE8300495D0/xx
Publication of SE8300495L publication Critical patent/SE8300495L/xx
Publication of SE454402B publication Critical patent/SE454402B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE8300495A 1982-02-01 1983-01-31 Nasalt administrerbar farmaceutisk komposition innehallande en ergotpeptidalkaloid samt ett xantin SE454402B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8202781 1982-02-01

Publications (3)

Publication Number Publication Date
SE8300495D0 SE8300495D0 (sv) 1983-01-31
SE8300495L SE8300495L (sv) 1983-08-02
SE454402B true SE454402B (sv) 1988-05-02

Family

ID=10528017

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8300495A SE454402B (sv) 1982-02-01 1983-01-31 Nasalt administrerbar farmaceutisk komposition innehallande en ergotpeptidalkaloid samt ett xantin

Country Status (27)

Country Link
JP (1) JPS58134017A (fr)
AT (1) AT385656B (fr)
AU (1) AU565613B2 (fr)
BE (1) BE895750A (fr)
CA (1) CA1197783A (fr)
CH (1) CH653555A5 (fr)
DE (1) DE3302949A1 (fr)
DK (1) DK164771C (fr)
ES (1) ES519450A0 (fr)
FI (1) FI81258C (fr)
FR (1) FR2539994B1 (fr)
GR (1) GR81320B (fr)
HK (1) HK59989A (fr)
HU (1) HU191512B (fr)
IE (1) IE54532B1 (fr)
IL (1) IL67822A (fr)
IT (1) IT1197558B (fr)
KE (1) KE3888A (fr)
LU (1) LU84613A1 (fr)
MY (1) MY8700766A (fr)
NL (1) NL192325C (fr)
NZ (1) NZ203117A (fr)
PH (1) PH22198A (fr)
PT (1) PT76166B (fr)
SE (1) SE454402B (fr)
SG (1) SG34389G (fr)
ZA (1) ZA83673B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
GB0910375D0 (en) * 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
CN111936140A (zh) * 2018-01-05 2020-11-13 英倍尔药业股份有限公司 通过精密鼻装置的双氢麦角胺的鼻内递送

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) * 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB1202885A (en) * 1966-12-22 1970-08-19 Sandoz Ltd Pharmaceutical compositions comprising alkaloids
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
FR2387035A1 (fr) * 1977-04-12 1978-11-10 Cassenne Lab Sa Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux
DE2831728C2 (de) * 1978-07-19 1982-12-23 Krewel-Werke Gmbh, 5208 Eitorf Arzneimittel zur Behandlung von Kopfschmerzen

Also Published As

Publication number Publication date
IT8347646A0 (it) 1983-02-01
IL67822A (en) 1988-02-29
JPH0253406B2 (fr) 1990-11-16
AU565613B2 (en) 1987-09-24
ES8502865A1 (es) 1985-02-01
KE3888A (en) 1989-09-01
IT1197558B (it) 1988-12-06
FR2539994B1 (fr) 1986-10-10
NL192325B (nl) 1997-02-03
DK164771B (da) 1992-08-17
CA1197783A (fr) 1985-12-10
FI830245A0 (fi) 1983-01-25
IE830187L (en) 1983-08-01
DE3302949A1 (de) 1983-08-11
BE895750A (fr) 1983-08-01
PH22198A (en) 1988-06-28
AU1085083A (en) 1983-08-11
ATA30383A (de) 1987-10-15
SG34389G (en) 1989-09-22
MY8700766A (en) 1987-12-31
DK164771C (da) 1992-12-28
PT76166A (en) 1983-02-01
FI81258B (fi) 1990-06-29
NZ203117A (en) 1986-12-05
NL8300325A (nl) 1983-09-01
LU84613A1 (fr) 1983-09-08
JPS58134017A (ja) 1983-08-10
DK38183D0 (da) 1983-01-31
CH653555A5 (de) 1986-01-15
DE3302949C2 (fr) 1992-05-21
AT385656B (de) 1988-05-10
NL192325C (nl) 1997-06-04
DK38183A (da) 1983-08-02
SE8300495L (sv) 1983-08-02
FR2539994A1 (fr) 1984-08-03
SE8300495D0 (sv) 1983-01-31
ZA83673B (en) 1984-09-26
GR81320B (fr) 1984-12-11
FI81258C (fi) 1990-10-10
IE54532B1 (en) 1989-11-08
PT76166B (en) 1986-02-04
HU191512B (en) 1987-02-27
FI830245L (fi) 1983-08-02
HK59989A (en) 1989-08-04
ES519450A0 (es) 1985-02-01
IL67822A0 (en) 1983-06-15

Similar Documents

Publication Publication Date Title
US11918655B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
US5169849A (en) Nasal pharmaceutical compositions
RU2421209C2 (ru) Фармацевтические композиции, содержащие циклоспорин
RU2380090C2 (ru) Назальные фармацевтические композиции и способы их применения
ES2891729T3 (es) Composición farmacéutica estable de dosis fija que comprende mometasona y olopatadina para la administración nasal
CA2822683A1 (fr) Compositions de bepostatine
HUE031470T2 (en) Preparations and methods of use containing azelastine
EA002174B1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
AU2023202420A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
WO2004091575A1 (fr) Preparation pharmaceutique nasale et ses methodes d'utilisation
AU2024201523A1 (en) Intranasal epinephrine formulations and methods for the treatment of disease
GB2162745A (en) Nasal compositions
SE454402B (sv) Nasalt administrerbar farmaceutisk komposition innehallande en ergotpeptidalkaloid samt ett xantin
GB2114001A (en) Nasal pharmaceutical compositions
KR20200125625A (ko) 모메타손 및 올로파타딘의 조합을 사용하는 소아 대상체의 알레르기성 비염의 치료
KR20010014366A (ko) 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8300495-2

Format of ref document f/p: F

NUG Patent has lapsed